Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a JAK inhibitor bring back hair in kids with severe alopecia?

NCT ID NCT07772492

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Sep 09, 2026 · Updated 5 times

Summary

This trial tests whether upadacitinib, an oral medication that calms the immune system, can help children with severe alopecia areata—a condition where the immune system attacks hair follicles, causing significant hair loss. Children aged 6 to 17 with at least 50% scalp hair loss will receive either upadacitinib or a placebo for about 160 weeks. The study measures how many achieve meaningful hair regrowth and monitors safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upadacitinib, an oral JAK inhibitor that reduces inflammation
What this could lead to
If successful, this could provide a new, approved treatment option for children with severe alopecia areata, potentially restoring significant hair growth.
What could go wrong
This is an early-stage test in a specific pediatric population; results may not apply to all patients, and side effects are possible. The trial is blinded and placebo-controlled, so outcomes are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Mar 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must have a diagnosis of severe alopecia areata with SALT score \>= 50 scalp hair loss at Screening and Baseline * No spontaneous scalp hair regrowth over the past 6 months * Participants will have current episode of alopecia areata of less than 8 years Exclusion Criteria: * Participants must not have a current diagnosis of primarily diffuse type of alopecia areata * Participants must not have a diagnosis of other types of alopecia that would interfere with evaluation of alopecia areata, including but not limited to female pattern hair loss, male pattern hair loss (androgenetic alopecia) Stage III or greater, traction alopecia, lichen planopilaris, discoid lupus, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, folliculitis decalvans, trichotillomania, and telogen effluvium * Participants must not have a diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of alopecia areata, including but not limited to seborrheic dermatitis, scalp psoriasis, AD, and tinea capitis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe alopecia areata are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe alopecia areata

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 3A Research - East location /ID# 283404

    RECRUITING

    El Paso, Texas, 79925, United States

  • Ada West Research /ID# 283063

    RECRUITING

    Meridian, Idaho, 83646, United States

  • Dawes Fretzin- Indianapolis /ID# 283498

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Dermatology Research Associates - Los Angeles /ID# 282821

    RECRUITING

    Los Angeles, California, 90045, United States

  • Pediatric Skin Research - Miami /ID# 283281

    RECRUITING

    Miami, Florida, 33156, United States

  • Skin Specialists /ID# 283358

    RECRUITING

    Omaha, Nebraska, 68144, United States

  • Texas Dermatology and Laser Specialists /ID# 282813

    RECRUITING

    San Antonio, Texas, 78218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.